As already known, GM-CSF inhibition turned out to broadly modulate monocytemacrophage activity by simultaneously reducing a spectrum of inflammatory cytokines,
including TNF-a.
3
We therefore suggest that the direct regulation of monocytemacrophage activity by Lenzilumab, with subsequent broad cytokines shutdown, could
provide a more favorable micro-environment where effector T cells could also be
protected from cytokine-induced apoptosis. This would preserve a non-exhausted T cell
phenotype, being more effective against infections and performing more potently T cell
specific antiviral immunity to achieve viral clearance.
Aware of the good safety profile of Lenzilumab in this current study and previous
analysis,1,5 the treatment is feasible and safe and the ongoing randomized phase III trial
(NCT04351152) will extensively confirm the lymphocyte recovery in Sars-CoV-2
infection and the impact of the drug on COVID-19 clinical improvement.
News 
Market Data 
Discover 
